GNRHR and erythema multiforme: Recently, the FDA approved elagolix, a nonpeptide small molecule GnRH receptor antagonist that suppresses luteinizing hormone and follicle‐stimulating hormone and correspondingly reduces E2 and progesterone, as a treatment for moderate to severe EM‐associated pain.